FINNENCE ▪ THE WIRE FILE
THE WIRE · № 62182
Company■ Unclear/unknown
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 12:00 UTC
LAST UPDATE2026-10-02 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Phase 3 GAD trial for Intra-Cellular Therapies signals pipeline progress but is not yet recruiting.
Early GAD trial signals pipeline progress
CATALYST TO WATCH
Trial enrollment and interim data
MAIN RISK
Trial may fail or face delays
FULL DISPATCH
Sponsor: Intra-Cellular Therapies, Inc.; Status: Not Yet Recruiting; Conditions: Generalized Anxiety Disorder; Interventions: JNJ-99245354, Placebo; Enrollment: 705 (estimated); First posted: 2026-10-02; NCT: NCT07856420
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDEli Lilly · LLY
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 12:11 UTC
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 12:11 UTC
→CORRELATIONshares Healthcare
Your health insurance premiums may take a big jump in 2027 — here's why2026-10-02 16:26 UTC
Your health insurance premiums may take a big jump in 2027 — here's why2026-10-02 16:26 UTC
←CORRELATIONshares Healthcare
Angel Aligner actualiza Torque Ridges a "Pressure Points" en Europa2026-10-02 08:46 UTC
Angel Aligner actualiza Torque Ridges a "Pressure Points" en Europa2026-10-02 08:46 UTC
←CORRELATIONshares Healthcare
New Research on Postpartum Depression vs. Depression: What Brain Imaging Reveals2026-10-02 09:00 UTC
New Research on Postpartum Depression vs. Depression: What Brain Imaging Reveals2026-10-02 09:00 UTC
←CORRELATIONshares Healthcare
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 20262026-10-02 09:00 UTC
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 20262026-10-02 09:00 UTC
←CORRELATIONshares LLY, Healthcare
19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt2026-10-02 09:41 UTC
19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt2026-10-02 09:41 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.